aclacinomycin has been researched along with Local Neoplasm Recurrence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, J; Jin, J; Shen, YJ; Wang, HF; Ye, XN; Zhang, Y; Zhu, HH; Zhu, L | 1 |
| Kanai, M; Kanno, M; Kobayashi, K; Kondo, K; Matano, S; Matsuda, T; Nakamura, S; Ohtake, S; Okafuji, K; Yoshida, T | 1 |
2 other study(ies) available for aclacinomycin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Treatment Outcome | 2023 |
Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prednisolone; Remission Induction; Time Factors | 1989 |